CPFP
NVAX icon

Clear Perspectives Financial Planning’s Novavax NVAX Stock Holding History

Clear Perspectives Financial Planning’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$51 – 220
2022
Q4 		$51 Buy
+5
New +$88 ﹤0.01% 230

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clear Perspectives Financial Planning's NVAX Position: Q1 2023 in Review

Clear Perspectives Financial Planning sold out of Novavax (NVAX) in Q1 2023, closing a stake of 5 shares — an estimated $51 sold.

Clear Perspectives Financial Planning first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $51 in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • Clear Perspectives Financial Planning reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • Clear Perspectives Financial Planning sold 5 Novavax shares in Q1 2023, an estimated $51.
  • Clear Perspectives Financial Planning first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
  • Clear Perspectives Financial Planning's Novavax position peaked at $51 in Q4 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Clear Perspectives Financial Planning's 13F filing for Q1 2023, filed 11 May 2023.